Home > Boards > US OTC > Medical - Equipment > RedHawk Holdings Corp. (SNDD)


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Granrok Member Profile
Followed By 10
Posts 1,126
Boards Moderated 0
Alias Born 03/19/15
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 10/22/2021 1:11:37 PM
Notification That Annual Report Will Be Submitted Late (nt 10-k) Edgar (US Regulatory) - 9/29/2021 6:03:19 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/4/2021 9:24:01 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/25/2021 9:56:37 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/25/2021 2:35:28 PM
RedHawk reports 9M results Seeking Alpha - 5/24/2021 4:25:44 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/24/2021 4:17:00 PM
REDHAWK REPORTS 3RD QUARTER RESULTS InvestorsHub NewsWire - 5/24/2021 4:15:00 PM
Statement of Ownership (sc 13g) Edgar (US Regulatory) - 5/20/2021 4:06:49 PM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) Edgar (US Regulatory) - 5/18/2021 4:28:20 PM
RedHawk reports FQ2 results Seeking Alpha - 2/23/2021 8:41:48 AM
REDHAWK REPORTS 2nd QUARTER RESULTS InvestorsHub NewsWire - 2/22/2021 5:30:00 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 2/22/2021 5:25:22 PM
Notification That Quarterly Report Will Be Submitted Late (nt 10-q) Edgar (US Regulatory) - 2/16/2021 7:28:30 AM
RedHawk spikes 10% on purchase of Med Tech Farms Seeking Alpha - 2/11/2021 2:31:47 PM
REDHAWK AGREES TO PURCHASE MED TECH FARMS LLC InvestorsHub NewsWire - 2/11/2021 12:00:00 PM
REDHAWK ANNOUNCES NEW ORDERS TOP $12.0 MILLION InvestorsHub NewsWire - 2/5/2021 12:00:00 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 12/21/2020 8:45:17 AM
REDHAWK ANNOUNCES RESULTS FOR THE QUARTER ENDED SEPTEMBER 30, 2020 InvestorsHub NewsWire - 12/18/2020 11:00:00 AM
REDHAWK LAUNCHES SALES OF ITS RE-DESIGNED SANDD PRO™ InvestorsHub NewsWire - 11/25/2020 11:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/24/2020 4:49:17 PM
Annual Report (10-k) Edgar (US Regulatory) - 11/18/2020 3:52:49 PM
REDHAWK REPORTS YEAR END RESULTS InvestorsHub NewsWire - 11/18/2020 1:00:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/5/2020 12:53:29 PM
Granrok   Wednesday, 11/18/20 03:59:58 PM
Re: None
Post # of 73665 


Branded Generic Pharmaceuticals

Under the terms of the EcoGen Agreement, Scarlett and its affiliate agreed to surrender to the Company 10 million shares of RedHawk’s then outstanding common stock, transfer to RedHawk Pharma approximately $300,000 of EcoGen’s preferred stock plus, other consideration in exchange for RedHawk Pharma assuming approximately $370,000 of obligations due to EcoGen.

A generic drug is a pharmaceutical drug that is substantially equivalent to a brand name product in dosage, strength, route of administration, quality, performance and intended use. Although they may not be associated with a particular company, generic drugs are subject to government regulations in the countries where they are dispensed. A generic drug must contain the same active ingredients as the original brand name formulation. In most cases, generic drugs become available after the patent afforded to a drug’s original developer expires. Once generic drugs enter the market, competition often leads to substantially lower prices for both the brand name drug and its generic equivalents. Clinicians in the United Kingdom are encouraged to write prescriptions for patent protected drugs by their generic name in preparation for such drugs losing their patent protected status, with the prescribed drug being dispensed to the patient by a community pharmacy. Pharmacists are obligated by law to dispense the brand that is written, should the clinician not use the generic name when prescribing a particular treatment, with all drugs being dispensed against a set tariff pricing structure. The pharmacist therefore procures the generic drug at the lowest available price from the wholesale supply chain, who in turn procures the lowest priced drug from any available manufacturer, ensuring that the generic drug market in the United Kingdom is purely driven by cost. The legal obligation on United Kingdom pharmacists to dispense a branded product if that is so prescribed presents the opportunity for the branded generic strategy of EcoGen. With a portfolio of widely prescribed generic drugs listed as trademarked branded generics, EcoGen can offer significant budgetary savings when compared to standard generics by offering these branded generics for sale at a price below the listed generic tariff. With UK Commissioning Groups (“CCG’s) being driven to find savings across their budgets where possible, we believe EcoGen’s branded generic strategy has been met favorably. Currently, we hold licenses to manufacture and sell Paracetamol, Glipizide and Omeprazole.

Paracetamol – Paracetamol is a pain reliever and a fever reducer used to treat many conditions such as headache, muscle aches, arthritis, backache, toothaches, colds, and fever.

Glipizide – Glipizide is an oral diabetes medicine that helps control blood sugar levels by helping the pancreas produce insulin. Glipizide is used together with diet and exercise to improve blood sugar control in adults with Type 2 diabetes mellitus.

Omeprazole – Omeprazole is used to reduce the amount of acid in the stomach in order to treat gastric or duodenal ulcers, gastroesophageal reflux disease (GERD), erosive esophagitis and hypersecretory conditions. Omeprazole is used to treat stomach infections caused by Helicobacter pylori bacteria.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences